— Sarepta Therapeutics, Inc. (NASDAQ: SRPT) reported a loss of $1.57 per share in the fourth quarter of 2019, vs $1.86 per share loss expected.
— Q4 revenue rose 19% to $100.1 million, vs. $98.8 million expected. Results were helped by an increase in demand for EXONDYS 51 in the U.S.
— Appointed biotech executive John C. Martin to Board of Directors. He is a former Gilead CEO.
— SRPT shares ended Wednesday’s regular trading session down 1.14%.
Listen to on-demand earnings calls and hear how management responds to analysts’ questions
Most Popular
American Express (AXP) Q2 2025 Earnings: Key financials and quarterly highlights
American Express Company (NYSE: AXP) reported its second quarter 2025 earnings results today. Consolidated total revenues, net of interest expense, were $17.9 billion, up 9% year-over-year, driven by increased Card
Netflix Q2 earnings jump on strong revenue growth; results beat estimates
Video streaming giant Netflix, Inc. (NASDAQ: NFLX) reported a sharp increase in revenue and profit for the second quarter of fiscal 2025. The numbers also beat analysts' estimates. The company's
Tesla Q2 Earnings Preview: Can energy gains offset EV demand Slump?
For Tesla Inc. (NASDAQ: TSLA), the new fiscal year has been quite challenging, with first-quarter sales falling to a three-year low amid production issues related to Model Y and increasing
